Wgi Dm LLC Acquires 118,029 Shares of Icon Plc $ICLR

Wgi Dm LLC raised its holdings in Icon Plc (NASDAQ:ICLR) by 9.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,396,009 shares of the medical research company’s stock after buying an additional 118,029 shares during the period. Icon comprises about 19.0% of Wgi Dm LLC’s holdings, making the stock its 3rd largest position. Wgi Dm LLC owned approximately 1.73% of Icon worth $254,381,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Toth Financial Advisory Corp bought a new stake in shares of Icon in the 4th quarter worth $27,000. Ameriflex Group Inc. bought a new position in Icon during the third quarter valued at about $33,000. Wilmington Savings Fund Society FSB boosted its position in Icon by 153.4% during the third quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock worth $58,000 after purchasing an additional 201 shares during the period. Pilgrim Partners Asia Pte Ltd bought a new position in Icon during the third quarter worth about $63,000. Finally, Johnson Financial Group Inc. bought a new position in Icon during the third quarter worth about $71,000. 95.61% of the stock is owned by institutional investors.

Icon Stock Down 0.6%

Shares of NASDAQ:ICLR opened at $116.38 on Friday. The stock’s 50-day moving average price is $109.72 and its 200-day moving average price is $144.82. Icon Plc has a 12-month low of $66.57 and a 12-month high of $211.00. The stock has a market capitalization of $9.40 billion, a P/E ratio of 15.75, a price-to-earnings-growth ratio of 3.04 and a beta of 1.23. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Robert W. Baird set a $119.00 target price on shares of Icon in a research report on Friday, February 13th. Weiss Ratings lowered shares of Icon from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, March 18th. Jefferies Financial Group set a $135.00 target price on shares of Icon and gave the stock a “buy” rating in a research report on Monday, February 23rd. BMO Capital Markets upgraded shares of Icon from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $100.00 to $130.00 in a research report on Thursday, March 26th. Finally, Zacks Research lowered shares of Icon from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 25th. Seven research analysts have rated the stock with a Buy rating, five have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $149.38.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.